332-OR: Association of Perceived Stress and Weight Loss in the National Diabetes Prevention Program (DPP)

An estimated 96 million Americans over the age of 18 have prediabetes. The Centers for Disease Control and Prevention’s National Diabetes Prevention Program (DPP) aims to promote lifestyle changes and weight loss to prevent or delay the onset of type 2 diabetes. While stress can play a significant role in weight management, little is known about the association between participant stress and weight loss in this program. The Scripps Whittier Diabetes Institute delivers the DPP within a large healthcare system in Southern California and administers the Perceived Stress Scale (PSS-10) at baseline and month 6 as part of the program. This analysis was conducted to examine the association between changes in stress and weight over 6 months. During a five-year timeframe that spanned the onset of the COVID-19 pandemic, and the transition from in-person to virtual delivery (October 2016 - January 2020), N = 341 individuals participated in the Scripps DPP. The majority of the participants were female (80.2%), married (65.4%), and reported an annual household income ≥ $24,000 (82.5%); 48.8% were non-Hispanic White. Baseline M(SD) age = 59.9 ± 13.66 and BMI = 32.15 ± 6.16. In a linear regression model, controlling for attendance, sex, and household income, a 1-point decrease in perceived stress was associated with a 0.28 lb. decrease in weight (p=0.02). At 6 months, overall mean weight loss was 4.24%, 8.13 lbs. The DPP addresses stress in one session during the core phase, with two additional sessions related to coping and problem solving. Collecting data with the PSS-10 can help provide additional insights into the effects of the DPP intervention. These findings indicate that reduction of stress over time in the DPP is associated with greater weight loss, thus highlighting the importance of the focus on stress management and coping in the DPP curriculum. Disclosure M.Chichmarenko: None. E.San diego: None. E.Soriano: None. S.R.Spierling bagsic: None. N.Orendain: None. A.Philis-tsimikas: Advisory Panel; Dexcom, Inc., Novo Nordisk A/S, Sanofi, Other Relationship; Medtronic, Research Support; Novo Nordisk A/S, Lilly, Viking Therapeutics, NIH - National Institutes of Health. A.L.Fortmann: Employee; Dexcom, Inc. M.Ruiz: None.